Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Komal JhaveriMatthew T ChangDejan JuricCristina SauraValentina GambardellaAnton MelnykManish R PatelVincent RibragCynthia X MaRaid AljumailyPhilippe L BedardJasgit C SachdevLara DunnHelen H WonJohn BondSurai JonesHeidi M SavageMaurizio ScaltritiTimothy R WilsonMichael C WeiDavid M HymanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Taselisib had limited activity in the tumor types tested and is no longer in development. This genome-driven study improves understanding of the activity, limitations, and resistance mechanisms of using PI3K inhibitors as monotherapy to target PIK3CA-mutant tumors.